Press Release
Perception Neuroscience's PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced positive data from its first Phase 1 clinical study demonstrating the safety
February 19, 2021
Press Release
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD
ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO,OTCQB: BNOEF , Germany: AU000000BNO5) ( Bionomics ) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc ( EmpathBio) , a wholly owned subsidiary of Germany-based CNS clinical
February 17, 2021
Press Release
atai Life Sciences to Collaborate with Massachusetts General Hospital to Accelerate Discovery of Mechanisms Underlying Therapeutic Effects of Psychedelic Agents
NEW YORK, Jan. 26, 2021 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company") , a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with Massachusetts General Hospital
January 26, 2021
Press Release
atai Life Sciences Acquires Majority Stake in Recognify Life Sciences to Develop Novel Treatment for Cognitive Impairment Associated with Schizophrenia
NEW YORK , Jan. 26, 2021 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company") , a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with Massachusetts General Hospital
January 12, 2021
Press Release
atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer
Dr. Rolando Gutierrez-Esteinou & Greg Weaver to Join Executive Management Team NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced
December 16, 2020
Press Release
ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round
Funding to support advancement of psychedelic and non-psychedelic compounds as well as innovative technologies to treat mental health disorders Participants include Apeiron Investment Group, Peter Thiel, Catalio Capital Management, Future Ventures, Galaxy Investment Partners, Falcon Edge Capital
November 23, 2020
Displaying 91 - 96 of 107